---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-249748"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:42:45.017970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics prices $55M public offering of common stock and pre-funded warrants

## Summary
- Offering of 14,252,670 shares at $1.93/share and pre-funded warrants to buy 14,247,330 shares at $1.929 each.
- Gross proceeds ~$55M; net proceeds ~$51.4M (or ~$59.1M if underwriters' option exercised).
- Net proceeds to fund Haduvio clinical trials for chronic cough (IPF and refractory) into 2026.
- Company does not intend to use proceeds for prurigo nodularis program; Phase 2b IPF trial targeted for H1 2023.
- Closing expected September 27, 2022; SVB Securities, Stifel, and Oppenheimer as joint bookrunners.

## SEC filing metadata
- accession: 0001193125-22-249748
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312522249748/0001193125-22-249748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312522249748/d378568d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-249748
- JSON: https://secwatch.observer/filing/0001193125-22-249748.json
- Plain text: https://secwatch.observer/filing/0001193125-22-249748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.